ECT Schizophrenia Serotonin Study

Schizophrenia Clinical Trial

Official title:

Serotonin Uptake to Lymphocytes and Citalopram Platelets Binding of Treatment-Resistant Schizophrenia Patients Before and After Electroconvulsive Therapy

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT00278668
• Other study ID #: 123.ctil
• Status: Not yet recruiting
• Phase: Phase 1
• First received: January 16, 2006
• Last updated: May 20, 2008
• Start date: October 2006
• Est. completion date: October 2006

Study information

• Verified date: May 2008
• Source: Sha’ar Menashe Mental Health Center
• Contact: Avi Peled, MD
• Phone: 972522844050
• Email: av_peled[@]netvision.net.il
• Is FDA regulated: No
• Health authority: Israel: Israeli Health Ministry Pharmaceutical Administration
• Study type: Observational

Clinical Trial Summary

We suggest to investigate serotonin uptake in schizophrenia patients receiving ECT

Description:

We suggest to investigate serotonin uptake in schizophrenia patients receiving ECT

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 15
• Est. completion date: October 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

Participants must meet DSM-IV criteria for schizophrenia, as assessed by the Structured Clinical Interview - Patient Version (SCID) (First et al., 1995).

Ages 18 -55 Men and/or women -

Exclusion Criteria:

1. History of neurological disorders, active substance abuse in the previous 3 months.

2. Estimated IQ less then 70.

3. SSRIs treatment 4 weeks prior to the study.

4. Any subject suffering from inflammatory fever disease will be excluded from the study.

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Schizophrenia

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Sha’ar Menashe Mental Health Center